

# Multiparametric Analysis of Factors Associated With Eosinophilic Chronic Rhinosinusitis With Nasal Polyps

Ear, Nose & Throat Journal  
2022, Vol. 101(6) NP256–NP262  
© The Author(s) 2020  
Article reuse guidelines:  
sagepub.com/journals-permissions  
DOI: 10.1177/0145561320960357  
journals.sagepub.com/home/ear



Gian Luca Fadda, MD<sup>1</sup>, Andrea Galizia, MD<sup>1</sup>, Giuseppe Galizia, PhD<sup>1</sup>,  
Paolo Castelnuovo, MD<sup>2</sup>, Maurizio Bignami, MD<sup>2</sup>, and Giovanni Cavallo, MD<sup>1</sup>

## Abstract

**Introduction:** Previous studies have reported a diverse range of threshold values for blood eosinophilia. In addition, a single predictive biomarker for eosinophilic chronic rhinosinusitis (CRS) with nasal polyps (ECRSwNP) has not yet been identified. **Objectives:** The aim of this study is to compare the clinical characteristics of ECRSwNP and non-ECRSwNP to evaluate the preoperative risk of tissue eosinophilia of chronic rhinosinusitis with nasal polyps (CRSwNP) through a multiparametric statistical analysis. **Methods:** One hundred ten patients with evidence of chronic polypoid rhinosinusitis were included in this study and clinical records were retrospectively reviewed. Eosinophilic CRSwNP was diagnosed based on the presence of at least 10 eosinophils per high-power field. The demographic and clinical features of ECRSwNP and non-ECRSwNP are described. The values of blood eosinophilia as predictors of tissue eosinophilia have been identified using receiver operating characteristic curves. As the predictive value of the identified cutoff through regression analysis was low, we evaluated whether other risk factors could be statistically associated with ECRSwNP, and from this, a new predictive model was proposed for the identification of eosinophilic nasal polyps before surgery. **Results:** We found that the best method for predicting ECRSwNP is based on a model having asthma, blood eosinophil percentage, posterior ethmoid value in Lund-Mackay score, and modified Lund-Kennedy score as explanatory variables. **Conclusions:** This study provides new data for a better understanding of the polypoid CRS endotypes, and the proposed model allows the endotype to be identified preoperatively.

## Keywords

nasal polyps, paranasal sinus diseases, paranasal sinuses, sinusitis, quality of life

## Introduction

Chronic rhinosinusitis (CRS) is a heterogeneous disease with a multifactorial pathogenesis, in which anatomy, microbiome, and the immune system are all considered to play a major role.<sup>1–4</sup> Based on clinical features, CRS can be subdivided into 2 phenotypes: CRS with nasal polyps (CRSwNP) and CRS without nasal polyps.<sup>5–7</sup> Furthermore, comorbidities of asthma and aspirin sensitivity tend to make the patient's condition more severe and difficult to treat, compared to CRSwNP alone.<sup>8,9</sup>

A classification into endotypes was necessary in the light of the pathophysiological mechanisms that determine and influence the clinical manifestations of the disease.<sup>10,11</sup> Chronic rhinosinusitis with nasal polyps with predominant eosinophil infiltration within the sinus tissue (ECRSwNP) versus non-ECRSwNP endotype is generally associated with asthma<sup>12</sup> and

poorer overall prognosis<sup>13,14</sup> and is clinically characterized by high serum eosinophilia and total immunoglobulin E, atopy,<sup>15</sup> greater extent of the disease, more severe endoscopic<sup>16</sup> and computed tomography (CT) scores,<sup>17</sup> greater symptom severity,<sup>18,19</sup> and greater olfactory dysfunction.<sup>20,21</sup> This is useful for both therapeutic management and preoperative briefing about

<sup>1</sup> Department of Otorhinolaryngology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy

<sup>2</sup> Department of Otorhinolaryngology, University of Insubria, Varese, Italy

Received: June 6, 2020; revised: August 29, 2020; accepted: August 31, 2020

### Corresponding Author:

GianLuca Fadda, Department of Otorhinolaryngology, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Italy.

Email: dott.fadda@gmail.com



**Table 1.** Summary of the Studies That Evaluated the Relationship Between Eosinophilia and Nasal Polyposis.<sup>a</sup>

Article, year	Cutoff eosinophilia	Sensitivity (%)	Specificity (%)	AUC	Definition of ECRSwNP
Sakuma et al, 2011 <sup>24</sup>	>6.00%	97.4	70.7	0.880	Clinical diagnosis + CT imaging
Hu et al, 2012 <sup>25</sup>	$>0.215 \times 10^3/\mu\text{L}$ >3.05%	74.280.3	86.575.3	0.8710.864	% tissue eosinophils > 10% total infiltrating cells
Snidvongs et al, 2012 <sup>13</sup>	$>0.300 \times 10^3/\mu\text{L}$ >4.4%	52.052.0	87.087.0		>10/HPF
Zuo et al 2014 <sup>15</sup>	$>0.160 \times 10^3/\mu\text{L}$ >2.05%	84.989.0	84.484.4	0.8730.863	>5/HPF
Gitomer et al, 2016 <sup>26,b</sup>	//	//	//	0.590	>10/HPF
Ho et al, 2018 <sup>27</sup>	$>0.240 \times 10^3/\mu\text{L}$ >4.27%	70.964.1	78.488.5	0.7920.797	>10/HPF
Fadda et al, 2020	$>0.365 \times 10^3/\mu\text{L}$ >4.15%	55.077.0	7662.0	0.6890.709	>10/HPF

Abbreviations: AUC, area under the curve; CT, computed tomography; ECRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; HPF, high-power field. <sup>a</sup>The average of the cutoff (excluding the article by Fadda et al) for blood eosinophilia in percentage terms is 3.95% (SD = 1.49), while the absolute value is  $0.22 \times 10^3/\mu\text{L}$  (SD = 0.05). This meta-analysis showed average values with a very high SD, explaining the impossibility nowadays to use an absolute cutoff value for blood eosinophilia. In our study, the value identified in percentage term (4.15%) falls within the CI of the meta-analysis performed. The same is not true of absolute value ( $>0.365 \times 10^3/\mu\text{L}$ ).

<sup>b</sup>No relationship between blood eosinophilia and tissue eosinophilia ( $P = .40$ ).

the likelihood of recurrence to help patients make informed, preference-based decisions.<sup>22,23</sup>

A surrogate biomarker of tissue eosinophilia is blood eosinophilia. Because previous studies have reported a diverse range of threshold values for blood eosinophilia (Table 1)<sup>13,15,24-27</sup> and a single predictive biomarker for ECRSwNP has not yet been identified, in this study, we propose a new predictive model based on the association between biomarkers and clinical features to enhance the reliability of prediction.

## Materials and Methods

### Aims

The first aim of this study is to describe the clinical features and objective parameters of CRS. The second aim is to evaluate whether higher blood eosinophilia could be statistically associated with the ECRSwNP endotype.

The third aim is to evaluate whether other risk factors (such as prior sinus surgery, smoking, gastroesophageal reflux disease [GERD], blood pressure, diabetes, asthma, allergic rhinitis, Sino-Nasal Outcome Test-22 [SNOT-22], Lund-Mackay [LM] scores, and modified Lund-Kennedy [MLK] scores) were statistically associated with the ECRSwNP endotype. Furthermore, another benefit of risk factor analysis is that a new predictive model arises for the identification of eosinophilic nasal polyps before surgery.

### Patient Population

The clinical records of 280 patients who underwent endoscopic sinus surgery (ESS) for chronic polypoid rhinosinusitis refractory to medical therapy were reviewed retrospectively. In these patients, ESS had been performed by the same surgeon at the ear, nose, and throat department of San Luigi Gonzaga Hospital in Turin, Italy, between March 2014 and March 2019. Exclusion criteria were as follows: patients younger than 18 years, acute infection, odontogenic CRS, antrochoanal polyps, cystic fibrosis, fungal sinusitis, systemic granulomatous disease, ciliary dyskinesia, and sinonasal tumor. As a result, 110 patients with evidence of chronic polypoid rhinosinusitis were included in this study.

### Classification of CRSwNP

Patients undergoing ESS were categorized into 2 groups: ECRSwNP and non-ECRSwNP, based on histological examination.<sup>1</sup>

### Study Tools

The clinical records of 110 selected patients were carefully reviewed on the basis of demographic data, including age and sex, previous sinus surgery, smoking, GERD, allergic rhinitis, history of asthma and aspirin sensitivity, diabetes mellitus, arterial hypertension, and preoperative medical therapy; SNOT-22 questionnaire before ESS, with all questions being answered based on a 0 to 5 scale (0: lowest intensity; 5: highest intensity)<sup>28</sup>; blood eosinophil percentage (EOS%) and count were measured before preoperative corticosteroid therapy, at least 3 months after withdrawing oral steroids; preoperative MLK endoscopic scoring system, based on polyp extent (0: none; 1: limited to the middle meatus; 2: beyond the middle meatus), edema (0: absent; 1: mild; 2: severe), and discharge (0: none; 1: clear; 2: thick and purulent)<sup>29</sup>; and preoperative CT images of the sinuses were graded according to the LM scoring system. Each sinus was graded 0 to 2 (0: no abnormalities; 1: partial opacification; 2: total opacification). The ostiomeatal complex was also graded 0 (not obstructed) or 2 (obstructed). A total score of 0 to 24 was assigned, and each side could be considered separately (0-12)<sup>30</sup>; sinus mucosal specimens were obtained intraoperatively and assessed by pathologists. Eosinophilic chronic rhinosinusitis with nasal polyps was diagnosed when histopathological assessment showed >10 eosinophils per high-power field (HPF). Histological examination is currently considered the diagnostic gold standard.<sup>14</sup>

### Statistical Analysis

**Receiver operating characteristic curve.** Receiver operating characteristic (ROC) curves based on the most significant clinical variables were compared with those obtained with the fitted values as output from the model.

**Optimal cutoff point.** The optimal cutoff points (optimal for both sensitivity and specificity) were defined as those for which the lowest values were yielded by the equation  $(1 - \text{sensitivity})^2 - (1 - \text{specificity})^2$ .<sup>2,31</sup>

**Logistic regression.** The probability of having eosinophilic nasal polyps (success) as a function of the main findings was evaluated by univariate logistic regression. Parameter estimates and 95% CI were calculated for each variable. Variables that were significantly correlated ( $P \leq .05$ ) with the logit of the probability of ECRSwNP were used in the subsequent multivariate logistic analysis.

**Stepwise regression analysis.** In order to select only the most significant predictive model (as the best linear combination of the significant variables), the stepwise logistic regression method was implemented. The automatic stepwise procedure was based on bidirectional elimination, according to the Akaike information criterion (AIC). The fitted values were used in subsequent analyses as possible predictors of ECRSwNP.

**Statistical tool.** Statistical analyses were conducted using RStudio version 1.1.456 with R engine version 3.5.1.

## Results

As mentioned in the Methods section, the first aim of the study was to describe the clinical features and objective parameters of CRS. The clinical profile of the 110 patients included in this study is presented in Table 2. Based on our histological criteria, among the 110 patients with CRSwNP, 65 (60%) were classified as ECRSwNP while 45 (40%) were non-ECRSwNP.

The second aim was to evaluate whether higher blood eosinophilia could be statistically associated with the ECRSwNP endotype. We analyzed the predictive ability of the absolute eosinophil blood count and percentage in the diagnosis of ECRSwNP. The ROC curves for both percentage and absolute count of blood eosinophils as predictors of ECRSwNP are shown in Figure 1. Looking at the data, we preferred using the percentage value rather than the absolute blood eosinophil count because the former had an area under the curve (AUC) of 0.709, while the latter had a value of 0.689. Next, we determined the best threshold value of EOS% and absolute count, which granted optimal sensitivity and specificity to discriminate ECRSwNP and non-ECRSwNP. Several cutoff points were selected. The lower the  $(1 - \text{sensitivity})^2 + (1 - \text{specificity})^2$  value, the better the accuracy of the predictor. The optimal value for EOS% was  $>4.15\%$ , which presented a sensitivity of 77% and a specificity of 62%, whereas for the absolute count, it was  $>0.365 \times 10^3/\mu\text{L}$ , which presented a sensitivity of 55% and a specificity of 76% (Table 1).<sup>13,15,24-27</sup> Both optimal values are indicated in blue in Figure 1. Since the ROC curves in our study have a lower AUC than other studies (Table 1),<sup>13,15,24-27</sup> we wondered if it would be possible to construct a predictor model of tissue eosinophilia that takes into account the remaining risk factors.

**Table 2.** Patient Demographics and Clinical Characteristics.

Characteristics	Total	Non-ECRSwNP	ECRSwNP
Number of CRSwNP (%)	110	45	65
Number of males (%)	74 (67.3)	32 (71.1)	42 (64.6)
Mean (SD) age, years	49.8 (15.2)	49.5 (15.2)	50 (15.2)
Allergy (%)	39 (35.4)	13 (28.8)	26 (40.0)
Asthma (%)	41 (37.3)	8 (17.7)	33 (50.7)
Eosinophilia, mean (SD), 1000/ $\mu\text{L}$	0.43 (0.4)	0.30 (0.2)	0.52 (0.5)
Eosinophilia, mean (SD), %	5.8 (4.0)	4.4 (3.3)	6.8 (4.2)
Number of hyper eosinophilia (%) <sup>a</sup>	67 (61.0)	17 (37.7)	50 (76.9)
Smoking (%)	16 (14.6)	8 (17.7)	8 (12.3)
Blood hypertension (%)	27 (24.6)	10 (22.2)	17 (26.1)
Diabetes mellitus (%)	2 (1.8)	0 (0)	2 (3.1)
GERD (%)	22 (20.0)	8 (17.7)	14 (21.5)
AERD triad (%)	8 (7.3)	0 (0)	8 (12.3)
Prior sinus surgery	39 (35.4)	16 (35.5)	23 (35.3)
Side			
Bilateral, n (%)	102 (92.7)	37 (82.2)	65 (100)
Right, n (%)	4 (3.6)	4 (8.8)	0 (0)
Left, n (%)	4 (3.6)	4 (8.8)	0 (0)
Type of surgery			
ESS, n (%)	87 (79.1)	32 (71.1)	55 (84.6)
FESS, n (%)	23 (20.9)	13 (28.8)	10 (15.4)
Septoplasty, n (%)	37 (33.6)	13 (28.8)	24 (36.9)
Average preoperative SNOT-22 (SD)	44 (21)	41 (17)	46 (23)
Average preoperative Lund-Mackay (SD)	15.7 (5.1)	13 (4.3)	17.5 (4.8)
Average modified Lund-Kennedy (SD)	7.7 (2.6)	6.4 (2.3)	8.6 (2.5)

Abbreviations: AERD, Aspirin-Exacerbated Respiratory Disease; CRSwNP, chronic rhinosinusitis with nasal polyps; ECRSwNP, eosinophilic chronic rhinosinusitis with nasal polyps; ESS, endoscopic sinus surgery; FESS, functional endoscopic sinus surgery; GERD, gastroesophageal reflux disease; SNOT-22, Sinonasal Outcome Test-22.


<sup>a</sup>Hyper eosinophilia evaluated according to the cutoff value of 4.15%.

The third aim was to evaluate whether other risk factors were statistically associated with the ECRSwNP endotype. To determine those risk factors, logistic regression analyses were conducted. First, the following variables were introduced into the univariate model: age, sex (male), prior sinus surgery, asthma, allergy rhinitis, GERD, smoking, diabetes, blood pressure, SNOT-22, blood eosinophil count (absolute number and percentage), and total and detailed LM scores, and MLK score. The factors significantly ( $P \leq .05$ ) associated with the probability of having ECRSwNP are summarized in Table 3. On the basis of the univariate analysis results, all significant factors were further introduced into a multivariate logistic model.

From this, the only 2 factors to show a statistically significant difference between groups were the MLK score ( $P = .014$ ) and posterior ethmoid (PE) sinus in the LM score ( $P = .047$ ; Table 3).

In addition, the stepwise logistic regression method was implemented to choose the multivariate model with the minimum number of the most significant predictive variables.

Through this automatic procedure for statistical model selection, based on minimizing the AIC, we looked for the best predictive model for ECRSwNP. In fact, ROC curves based on the most significant variables showed the highest AUC (+17% compared with the AUC based on the single EOS%). These results are summarized in Table 4 and depicted in Figure



**Figure 1.** Receiver operating characteristic curves of blood eosinophilia. The predictive ability was calculated based on the area under the curve (AUC). An AUC with a value close to 1 indicates an excellent ability to discriminate. Receiver operator characteristic curves demonstrate a poor utility of blood eosinophil absolute count and percentage for predicting eosinophilic chronic rhinosinusitis with nasal polyps in the population under analysis. The blue numbers are those that minimize the equation  $(1 - \text{sensitivity})^2 + (1 - \text{specificity})^2$ .

2. Therefore, we found that the best (for both sensitivity and specificity) method for predicting ECRSwNP is based on the model having asthma, EOS%, and PE sinus in the LM score and MLK score as explanatory variables. The preferred model is the following:

$$\begin{aligned} \text{logit}(\pi_{\text{ECRSwNP}}) = & - 3.826 + 0.238 \text{ MLK} + 0.581 \text{ PE} \\ & + 0.127 \text{ EOS\%, if without asthma,} \\ & - 2.951 + 0.238 \text{ MLK} + 0.581 \text{ PE} \\ & + 0.127 \text{ EOS\%, if with asthma.} \end{aligned} \tag{1}$$

**Discussion**

Unlike classifications based on CRS phenotyping, which differentiate disease variants according to observable clinical features,<sup>7</sup> classifications based on endotyping are based on immunohistological biomarkers involved in disease pathophysiology.<sup>32,33</sup> Not only has the current interest in the endotypes of CRS (derived from previous research on asthma)<sup>34,35</sup> advanced a new diagnostic scheme, but it has also demonstrated therapeutic implications.<sup>23,36</sup> As reported in the literature, one of the most widely used biomarkers for endotyping CRSwNP is the degree of tissue eosinophilia,<sup>14,37,38</sup> based on which good responders to a specific treatment can be selected and the risk of recurrence after sinus surgery and for comorbidities such as asthma can be predicted.<sup>23</sup> Such preoperative knowledge is, therefore, of considerable use, and several authors have evaluated blood eosinophilia as a submarker of tissue eosinophilia (Table 1).<sup>13,15,24-27</sup> The meta-analysis summarized in Table 1 presents very different cutoff values of blood eosinophils as a marker of tissue eosinophilia, and this may be due to the lack of a clear and unambiguous definition of ECRSwNP. Serum eosinophil count can also be falsely elevated by comorbid parasite infection, allergy, autoimmune disorders, or adverse drug events.<sup>39</sup> Gitomer et al<sup>26</sup> did not find

**Table 3.** Logistic Regression Analysis of Findings Associated With ECRwNP.<sup>a</sup>

Findings	Univariate				Multivariate				
	$\beta_1$	LL <sub>2.5%</sub>	UL <sub>97.5%</sub>	P value	$\acute{I}$	$\beta_1$	LL <sub>2.5%</sub>	UL <sub>97.5%</sub>	P value
Intercept					0	-4.415	-7.423	-1.909	.001
Lund-Mackay	0.205	0.115	0.308	<.001	1	-0.009	-0.295	0.354	.956
MLK	0.372	0.201	0.564	<.001	2	0.304	0.068	0.557	.014
AE	0.811	0.403	1.248	<.001	3	-0.016	-0.823	0.780	.968
PE	0.893	0.541	1.296	<.001	4	0.661	0.051	1.319	.047
SS	0.701	0.382	1.062	<.001	5	0.322	-0.233	0.894	.259
Asthma	1.562	0.694	2.522	.001	6	0.699	-0.504	1.948	.257
EOS%	0.204	0.081	0.347	.003	7	0.101	-0.113	0.306	.334
EOS (10 <sup>3</sup> / $\mu$ L)	2.574	0.826	4.725	.01	8	0.936	-0.531	4.330	.355
F	0.285	0.022	0.561	.037	9	-0.472	-1.140	0.084	.129

Abbreviations: AE, anterior ethmoid; EOS%, blood eosinophil percentage (%); F, frontal; LL<sub>2.5%</sub>, lower limit of the 95% CI; MLK, modified Lund-Kennedy; PE, posterior ethmoid; SS, sphenoid sinus; UL<sub>97.5%</sub>, upper limit of the 95% CI.


<sup>a</sup>In the univariate analysis,  $\beta_1$  is the estimate of the parameter correlating logit to the specific finding variable, according to the logistic regression model  $\text{logit}(\pi_{\text{ECRSwNP}}) = \beta_0 + \beta_1 + \dots + X$ , where X is one specific finding. In the multivariate analysis,  $\beta_1$  is the estimate of the parameter correlating logit to their specific finding variable according to the multivariate logistic model  $\text{logit}(\pi_{\text{ECRSwNP}}) = \beta_0 + \beta_1 + \dots + LX + \beta_2 + \dots + PE + \dots + \beta_{10}$ .



**Table 4.** Predictive Models for ECRSwNP That Allow the Specificity and Sensitivity to be Increased Compared to the Best Case Based on a Single Predictor.

Model	AUC	Cutoff	SE (%)	SP (%)	$(1 - \text{sensitivity})^2 + (1 - \text{specificity})^2$
Without asthma: −3.826 + 0.238 MLK + 0.581 PE + 0.127 EOS%With asthma: −2.951 + 0.238 MLK + 0.581 PE + 0.127 EOS%	0.831	0.606	80.0	75.4	0.101
PE	0.773	2.480	75.6	64.6	0.185
EOS%	0.709	4.150	62.2	76.9	0.196
Lund-Mackay	0.753	13.500	62.2	75.4	0.203
MLK	0.741	6.500	60.0	76.9	0.213
AE	0.700	3.460	71.1	63.1	0.220
SS	0.732	1.490	55.6	75.4	0.258
EOS (10 <sup>3</sup> /μL)	0.689	0.360	75.6	55.4	0.259
Asthma	0.665	0.450	82.2	50.8	0.274
F	0.613	2.490	77.8	47.7	0.323

Abbreviations: AE, anterior ethmoid; AUC, area under the curves; EOS%, blood eosinophil percentage (%); F, frontal; MLK, modified Lund Kennedy; PE, posterior ethmoid; SE, sensitivity; SP, specificity; SS, sphenoid sinus.



**Figure 2.** Receiver operating characteristic curves of different predictive models of ECRSwNP. The predictive ability was calculated based on the AUC. Through the new models that combine different markers of tissue eosinophilia, we obtain higher AUC values and therefore a predictive model with better sensitivity and specificity. AE indicates anterior ethmoid; AUC, area under the curve; ECRSwNP, eosinophilic chronic rhinosinusitis (CRS) with nasal polyps; EOS%, blood eosinophil percentage (%); EOS 1000/μL, absolute number ( $\times 10^3/\mu\text{L}$ ); F, frontal; LM, Lund-Mackay; MLK, modified Lund-Kennedy; PE, posterior ethmoid; SS, sphenoid sinus.

correlations because they were not able to eliminate either topical or systemic steroid use as a confounder of tissue eosinophilia. In keeping with Soler et al,<sup>14</sup> we defined ECRSwNP on the basis of the presence of an absolute count of tissue eosinophils  $>10/\text{HPF}$ , which is associated with worse general outcomes and prognosis. Our identified cutoff values (4.85% and  $0.295 \times 10^3/\mu\text{L}$ ) fall within the CI of our meta-analysis (Table 1).

Since a single parameter does not possess sufficient accuracy to be regarded as clinically relevant, we looked for a predictive model for ECRSwNP that would take into account several parameters at a time. The model proposed in this study (see Equation 1) takes into account the presence or absence of asthma, MLK, PE, and the EOS%. This allows the specificity and sensitivity to be increased compared to the best case based on a single predictor (Table 4). This information allows individualized therapeutic management taking into account the patient's endpoint.

Unlike other studies relying on the original Lund-Kennedy score, we used MLK because it is the only scoring system that shows a positive correlation with SNOT-22 in both preoperative and postoperative patients, suggesting its applicability to all patients, regardless of their surgical state.<sup>29</sup> In our study, in both the univariate logistic regression analyses and the multivariate logistic relationship, we found a statistically significant correlation between the MLK value and tissue eosinophilia. In addition, in the new model proposed for preoperative assessment of tissue eosinophilia, the most significant marker is MLK and not the percentage value of blood eosinophils. In conclusion, this study helps clarify which factors are most associated with ECRSwNP in order to assist in defining endpoints.

### Authors' Note

GianLuca Fadda made substantial contributions to the work reported in this manuscript and as a surgeon. Paolo Castelnuovo and Maurizio Bignami contributed to the conception or design of the work, revised it critically for important intellectual content, and gave final approval of the version to be published. Andrea Galizia and Giovanni Cavallo made substantial contributions to the preparation of patients undergoing surgery and gave final approval of the version to be published. Giuseppe Galizia underwent statistical analysis, interpreted data in the study, and gave final approval of the version to be published.

### Declaration of Conflicting Interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

### Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

### References

1. Fokkens W, Lund V, Mullol J. European Position Paper on Rhinosinusitis and Nasal Polyps 2007. European Position Paper on Rhinosinusitis and Nasal Polyps Group. *Rhinol Suppl.* 2007;20: 1-136.

2. Bachert C, Pawankar R, Zhang L, et al. ICON: chronic rhinosinusitis. *World Allergy Organ J*. 2014;7(1):1-28. <https://doi.org/10.1186/1939-4551-7-25>
3. Fadda GL, Rosso S, Aversa S, et al. Multiparametric statistical correlations between paranasal sinus anatomic variations and chronic rhinosinusitis. *Acta Otorhinolaryngol Ital*. 2012;32(4):244-251.
4. Ivanchenko OA, Karpishchenko SA, Kozlov RS, et al. The microbiome of the maxillary sinus and middle nasal meatus in chronic rhinosinusitis. *Rhinology*. 2016;54(1):68-74. <https://doi.org/10.4193/Rhin15.018>
5. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. *Mayo Clin Proc*. 2011;86(5):427-443. <https://doi.org/10.4065/mcp.2010.0392>
6. Fokkens W, Lund V, Mullol J. EP3OS 2007: European position paper on rhinosinusitis and nasal polyps 2007. A summary for otorhinolaryngologists. *Rhinology*. 2007;45(2):97-101.
7. Fokkens WJ, Lund VJ, Mullol J, et al. EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists. *Rhinology*. 2012;50(1):1-12. <https://doi.org/10.4193/Rhino50E2>
8. López-Chacón M, Mullol J, Pujols L. Clinical and biological markers of difficult-to-treat severe chronic rhinosinusitis. *Curr Allergy Asthma Rep*. 2015;15(5):19. <https://doi.org/10.1007/s11882-015-0520-6>
9. Pearlman AN, Chandra RK, Chang D, et al. Relationships between severity of chronic rhinosinusitis and nasal polyposis, asthma, and atopy. *Am J Rhinol Allergy*. 2009;23(2):145-148. <https://doi.org/10.2500/ajra.2009.23.3284>
10. Dennis SK, Lam K, Luong A. A review of classification schemes for chronic rhinosinusitis with nasal polyposis endotypes. *Laryngoscope Investig Otolaryngol*. 2016;1(5):130-134.
11. DeConde AS, Smith TL. Classification of chronic rhinosinusitis—working toward personalized diagnosis. *Otolaryngol Clin North Am*. 2017;50(1):1-12. <https://doi.org/10.1016/j.otc.2016.08.003>
12. Ardehali MM, Amali A, Bakhshaei M, Madani Z, Amiri M. The comparison of histopathological characteristics of polyps in asthmatic and nonasthmatic patients. *Otolaryngol Head Neck Surg*. 2009;140(5):748-751. <https://doi.org/10.1016/j.otohns.2009.01.027>
13. Snidvongs K, Lam M, Sacks R, et al. Structured histopathology profiling of chronic rhinosinusitis in routine practice. *Int Forum Allergy Rhinol*. 2012;2(5):376-385. <https://doi.org/10.1002/alr.21032>
14. Soler ZM, Sauer D, Mace J, Smith TL. Impact of mucosal eosinophilia and nasal polyposis on quality of life outcomes after sinus surgery. *Otolaryngol Head Neck Surg*. 2010;142(1):64-71. <https://doi.org/10.1016/j.otohns.2009.10.005>
15. Zuo K, Guo J, Chen F, et al. Clinical characteristics and surrogate markers of eosinophilic chronic rhinosinusitis in southern china. *Eur Arch Otorhinolaryngol*. 2014;271(9):2461-2468. <https://doi.org/10.1007/s00405-014-2910-0>
16. Armengot M, Garin L, Carda C. Eosinophil degranulation patterns in nasal polyposis: an ultrastructural study. *Am J Rhinol Allergy*. 2009;23(5):466-470. <https://doi.org/10.2500/ajra.2009.23.3357>
17. Poznanovic SA, Kingdom TT. Total IgE levels and peripheral eosinophilia: correlation with mucosal disease based on computed tomographic imaging of the paranasal sinus. *Arch Otolaryngol Head Neck Surg*. 2007;133(7):701-704.
18. Sun DI, Joo YH, Auo HJ, Kang JM. Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis. *Eur Arch Otorhinolaryngol*. 2009;266(7):981-986. <https://doi.org/10.1007/s00405-008-0872-9>
19. Soler ZM, Sauer DA, Mace J, Smith TL. Relationship between clinical measures and histopathologic findings in chronic rhinosinusitis. *Otolaryngol Head Neck Surg*. 2009;141(4):454-461. <https://doi.org/10.1016/j.otohns.2009.06.085>
20. Shin SH, Ye MK, Kim JK, Cho CH. Histological characteristics of chronic rhinosinusitis with nasal polyps: recent 10-year experience of a single center in Daegu, Korea. *Am J Rhinol Allergy*. 2014;28(2):95-98. <https://doi.org/10.2500/ajra.2014.28.4003>
21. Soler ZM, Sauer DA, Mace JC, Smith TL. Ethmoid histopathology does not predict olfactory outcomes after endoscopic sinus surgery. *Am J Rhinol Allergy*. 2010;24(4):281-285. <https://doi.org/10.2500/ajra.2010.24.3477>
22. Harvey RJ, Wallwork BD, Lund VJ. Anti-inflammatory effects of macrolides: applications in chronic rhinosinusitis. *Immunol Allergy Clin North Am*. 2009;29(4):689-703. <https://doi.org/10.1016/j.iac.2009.07.006>
23. Kim DW, Cho SH. Emerging endotypes of chronic rhinosinusitis and its application to precision medicine. *Allergy Asthma Immunol Res*. 2017;9(4):299-306. <https://doi.org/10.4168/air.2017.9.4.299>
24. Sakuma Y, Ishitoya J, Komatsu M, et al. New clinical diagnostic criteria for eosinophilic chronic rhinosinusitis. *Auris Nasus Larynx*. 2011;38(5):583-588. <https://doi.org/10.1016/j.anl.2011.01.007>
25. Hu Y, Cao PP, Liang GT, Cui YH, Liu Z. Diagnostic significance of blood eosinophil count in eosinophilic chronic rhinosinusitis with nasal polyps in Chinese adults. *Laryngoscope*. 2012;122:498-503. <https://doi.org/10.1002/lary.22507>
26. Gitomer SA, Fountain CR, Kingdom TT, et al. Clinical examination of tissue eosinophilia in patients with chronic rhinosinusitis and nasal polyposis. *Otolaryngol Head Neck Surg*. 2016;155(1):173-178. <https://doi.org/10.1177/0194599816637856>
27. Ho J, Hamizan AW, Alvarado R, et al. Systemic predictors of eosinophilic chronic rhinosinusitis. *Am J Rhinol Allergy*. 2018;32(4):252-257. <https://doi.org/10.1177/1945892418779451>
28. Rudmik L, Soler ZM, Mace JC, et al. Using preoperative SNOT-22 score to inform patient decision for endoscopic sinus surgery. *Laryngoscope*. 2015;125(7):1517-1522. <https://doi.org/10.1002/lary.25108>
29. Psaltis AJ, Li G, Vaezaefshar R, Cho KS, Hwang PH. Modification of the Lund-Kennedy endoscopic scoring system improves its reliability and correlation with patient-reported outcome measures. *Laryngoscope*. 2014;124(10):2216-2223. <https://doi.org/10.1002/lary.24654>
30. Lund VJ, Mackay IS. Staging in rhinosinusitis. *Rhinology*. 1993;31(4):183-184.
31. Perkins NJ, Schisterman EF. The inconsistency of “optimal” cutpoints obtained using two criteria based on the receiver operating characteristic curve. *Am J Epidemiol*. 2006;163(7):670-675.

32. Tomassen P, Vandeplas G, Van Zele T, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. *J Allergy Clin Immunol*. 2016;137(5):1449-1456. <https://doi.org/10.1016/j.jaci.2015.12.1324>
33. Hamilos DL. Chronic rhinosinusitis endotyping: sharpening the focus on inflammation. *J Allergy Clin Immunol*. 2016;137(5):1457-1459. <https://doi.org/10.1016/j.jaci.2016.03.011>
34. Lötvall J, Akdis CA, Bacharier LB, et al. Asthma endotypes: a new approach to classification of disease entities within the asthma syndrome. *J Allergy Clin Immunol*. 2011;127(2):355-360. <https://doi.org/10.1016/j.jaci.2010.11.037>
35. Wenzel S. Severe asthma: from characteristics to phenotypes to endotypes. *Clin Exp Allergy*. 2012;42(5):650-658. <https://doi.org/10.1111/j.1365-2222.2011.03929.x>
36. Bidder T, Sahota J, Rennie C, et al. Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together – a real life study. *Rhinology*. 2018;56(1):42-45. <https://doi.org/10.4193/Rhin17.139>
37. Czerny MS, Namin A, Gratton MA, Antisdell JL. Histopathological and clinical analysis of chronic rhinosinusitis by subtype. *Int Forum Allergy Rhinol*. 2014;4(6):463-469. <https://doi.org/10.1002/alr.21304>
38. Thompson CF, Price CP, Huang JH, et al. A pilot study of symptom profiles from a polyp vs an eosinophilic-based classification of chronic rhinosinusitis. *Int Forum Allergy Rhinol*. 2016;6(5):500-507. <https://doi.org/10.1002/alr.21687>
39. Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. *J Allergy Clin Immunol*. 2010;126(1):39-44. <https://doi.org/10.1016/j.jaci.2010.04.011>